Physician profile
Danielle Ready
NPI 1699361832
$4,086.96
in general payments reported to CMS, 2019-2025
23 companies · $865 in 2025
The $865 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $868 · 2023: $1,347 · 2024: $1,007 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $880.23 | 2022-2025 | |
| Lundbeck LLC | $505.17 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $416.69 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $355.19 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $343.75 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $272.90 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $203.55 | 2022-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $152.08 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $138.84 | 2022-2025 | Rexulti |
| Tris Pharma INC | $130.93 | 2022-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $124.75 | 2022-2025 | Aplenzin |
| Alkermes, INC. | $107.43 | 2023-2024 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $86.96 | 2022-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $80.30 | 2022-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $59.97 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $57.46 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $46.02 | 2022-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $29.74 | 2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $22.44 | 2023 | Ingrezza |
| Noven Therapeutics, LLC | $19.70 | 2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $18.70 | 2022 | |
| Avion Pharmaceuticals | $17.64 | 2023 | Methylphenidate Hydrochloride |
| Idorsia Pharmaceuticals US INC | $16.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ready listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.